Age-Adapted Moderate-Dose Induction and Flexible Outpatient Postremission Therapy for Elderly Patients with Acute Lymphoblastic Leukemia

References

• Johnson P. R. E., Liu Yin J.A. Acute myeloid leukaemia in the elderly, biology and treatment. Brit. J. Haematol 1993; 83: 1–6
   PubMed Web of Science ®Google Scholar
• Kantarjian H.M., O'Brien S., Smith T., Estey E.H., Beran M., Preti A., Pierce S., Keating M.J. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vin-cristine-adriamycin-dexamethasone (VAD) regimen. Brit. J. Haematol 1994; 88: 94–100
   PubMed Web of Science ®Google Scholar
• Taylor P. R. A., Reid M.M., Bown N., Hamilton P.J., Proctor S.J. Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood 1992; 80: 1813–1817
   PubMed Web of Science ®Google Scholar
• Delannoy A., Ferrant A., Bosly A., Chatelain C., Doyen C., Martiat P., Michaux J.L., Sokal G. Acute lymphoblastic leukemia in the elderly. Eur. J. Haematol. 1990; 45: 90–93
   PubMed Web of Science ®Google Scholar
• Virgilio J.F., Moscinski L.C., Ballester O.F., Corrado C., Guida C., Balducci L., Saba H. Acute lymphocytic leukemia (ALL) in elderly patients. Hematol. Oncol. 1993; 11: 121–126
   PubMed Web of Science ®Google Scholar
• Hussein K.K., Dahlberg S., Head D., Waddell C.C., Dabich L., Weick J.K., Morrison F., Saiki J.H., Metz E., Rivkin S.E., Grever M.R., Boldt D., the Southwest Oncology Group. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73: 57–63
   PubMed Web of Science ®Google Scholar
• Gaynor J., Chapman D., Little C., McKenzie S., Miller W., Andreeff M., Arlin Z., Berman E., Kempin S., Gee T., Clarkson B. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J. Clin. Oncol. 1988; 6: 1014–1030
   PubMed Web of Science ®Google Scholar
• Hoelzer D., Thiel E., Ludwig W.D., Loffler H., Buchner T., Freund M., Heil G., Hiddemann W., Maschmeyer G., Volkers B., Gokbuget N., Aydemir U., for the German Adult all Study Group. Follow-up of the first two successive German multi-centre trials for adult ALL (01/81 and 02/84). Leukemia 1993; 7(Suppl. 2)S130–S134
   PubMed Web of Science ®Google Scholar
• Barnett M.J., Greaves M.F., Amess J. A. L., Gregory W.M., Rohatiner A. Z. S., Dhaliwal H.S., Slevin M.L., Biruls R., Malpas J.S., Lister T.A. Treatment of acute lymphoblastic leukaemia in adults. Brit. J. Haematol. 1986; 64: 455–468
   PubMed Web of Science ®Google Scholar
• Ellison R.R., Mick R., Cuttner J., Schiffer C.A., Silver R.T., Henderson E.S., Woliver T., Royston I., Davey F.R., Glicksman A.S., Bloomfield C.D., Holland J.F. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J. Clin. Oncol 1991; 9: 2002–2015
   PubMed Web of Science ®Google Scholar
• Bassan R., Battista R., Corneo G., Rossi G., Lambertenghi-Deliliers G., Viero P., Rambaldi A., D'Emilio A., Neonato M.G., Pogliani E., Oriani A., Izzi T., Dini E., Barbui T. Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome. Leuk. Lymph. 1993; 11: 105–110
   PubMed Web of Science ®Google Scholar
• Bassan R., Battista R., Viero P., Pogliani E., Rossi G., Lambertenghi-Deliliers G., Rambaldi A., D'Emilio A., Buelli M., Borleri G., Corneo G., Dini E., Barbui T. Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen. Semin. Oncol 1993; 20(Suppl. 8)39–16
   PubMed Web of Science ®Google Scholar
• Hermans A., Gow J., Selleri L., von Lindern M., Hagemeijer A., Wiedemann L., Grosveld G. bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 1988; 1: 628–633
   Google Scholar
• Mandelli F., Petti M.C., Ardia A., Di Pietro N., Di Raimondo F., Ganzina F., Falconi E., Geraci E., Ladogana S., Latagliata R., Malleo C., Nobile F., Petti N., Rotoli B., Specchia G., Tabilio A., Resegotti L. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur. J. Cancer 1991; 27: 750–755
   PubMed Web of Science ®Google Scholar
• Bassan R., Cornelli P.E., Battista R., Terzi F., Buelli M., Rambaldi A., Viero P., D'Emilio A., Dini E., Barbui T. Intensive retreatment of adults and children with acute lymphoblastic leukaemia. Hematol. Oncol 1992; 10: 105–110
   PubMed Web of Science ®Google Scholar
• Bassan R., Battista R., Montaldi A., Rambaldi A., D'Emilio A., Viero P., Borleri G., Buelli M., Dini E., Barbui T. Reinforced HEAV'D therapy for adult acute lymphoblastic leukemia: improved results and revised prognostic criteria. Hematol. Oncol 1993; 11: 169–177
   PubMed Web of Science ®Google Scholar
• Ottmann O.G., Hoelzer D., Gracien E., Kelly P., Ganser A., Reutzel R., Lipp T., Busch F.W., Scwhonzen M., Wandt H., Heil G., Koch P., Heyll A., Meyer P., Bentz M., Peter S., Diedrich H., Kolbe K., Gral M. Simultaneous R-metHuG-CSF and chemo-radiotherapy during induction treatment in adult ALL: a randomized trial (Abstract). Brit. J. Haematol 1994; 87(Suppl 1)17a
   Google Scholar
• Larson R.A., Linker C.A., Dodge R.K., George S.L., Davey F.R., Frankel S.R., Powell B.L., Schiffer C.A. Granulocyte-colony stimulating factor (filgrastim: G-CSF) reduces the time to neutrophil recovery in adults with acute lymphoblastic leukemia receiving intensive remission induction chemotherapy: Cancer and Leukemia Group B study 9111. Proc. Am. Soc. Clin Oncol 1994; 13: 305a
   Google Scholar
• Hoelzer D. Treatment of acute lymphoblastic leukemia. Semin. Hematol 1994; 31: 1–15
   PubMed Web of Science ®Google Scholar
• Greaves M. Stem cell origins of leukaemia and curability. Brit. J. Cancer 1993; 67: 413–423
   PubMed Web of Science ®Google Scholar
• Goasguen J.E., Dossot J.-M., Fardel O., Le Mee F., Le Gall E., Leblay R., LePrise P.Y., Chaperon J., Fauchet R. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394–2394
   PubMed Web of Science ®Google Scholar
• Smetsers T. F. C. M., Skorski T., van de Locht L. T. F., Wessels H. M. C., Pennings A. H. M., de Witte T., Calabretta B., Mensink E. J. B. M. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 1994; 8: 129–140
   PubMed Web of Science ®Google Scholar
• Manabe A., Coustan-Smith E., Kumagai M., Behm F.G., Raimondi S.C., Pui C.H., Campana D. lnterleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood 1994; 83: 1731–1737
   PubMed Web of Science ®Google Scholar
• Smets L.A., Van den Berg J., Acton D., Top B., Van Rooij H., Verwijs-Janssen M. BCL-2 expression and mithocondrial activity in leukemic cells with different sensitivity to glucocorti-coid-induced apoptosis. Blood 1994; 84: 1613–1619
   PubMed Web of Science ®Google Scholar
• Hsiao M.H., Yu A.L., Yeargin J., Ku D., Haas M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with relapse phase. Blood 1994; 83: 2922–2930
   PubMed Web of Science ®Google Scholar
• Beck J., Handgretinger R., Dopfer R., Klingebiel T., Niethammer D., Gekeler V. Expression of mdr 1, mrp, topoisomerase IIα/β”, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Brit. J. Haematol 1995; 89: 356–363
   PubMed Web of Science ®Google Scholar